Journal of Liver

Comans EFI

Publications

• Research Article
  Stereotactic Ablative Radiotherapy to Treat Colorectal Liver Metastases: Ready for Prime-Time?
  Author(s): Nielsen K, Van der Sluis WB, Scheffer HJ, Meijerink MR, Comans EFI, Slotman BJ, Meijer S, Van den Tol MP and Haasbeek CJANielsen K, Van der Sluis WB, Scheffer HJ, Meijerink MR, Comans EFI, Slotman BJ, Meijer S, Van den Tol MP and Haasbeek CJA
  
  Background: Stereotactic Ablative Radiotherapy (SABR) is a non-invasive treatment option for patients with Colorectal Liver Metastases (CRLM) ineligible for resection or thermal ablation. The aim of our study was to evaluate local control, disease progression, toxicity, complications and survival after SABR of CRLM. We also discuss the place of SABR in the treatment algorithm of CRLM. Methods: Patients with CRLM, ineligible for resection or thermal ablation and suitable for SABR, were included in our database and retrospectively analyzed. Patients with oligometastases <5 cm without the presence of other organs in the target area are eligible for SABR. Follow-up imaging was conducted at 3 and 6 months following SABR and 6-monthly thereafter. Total delivered dose per lesion was 54-60 Gy, divided over 3-12 fractions, depending on the dose co.. View More»
  DOI: 10.4172/2167-0889.1000139

  Abstract PDF